The Portuguese National Laboratory of Medicines (LNM), connected to the Portuguese Army, is progressing in the production of medical cannabis, including the construction of specialized clean rooms, as part of an effort to provide alternative or supplementary medical treatments for Portuguese patients. The LNM is also a key participant several other projects advancing uses for cannabis.
The Portuguese National Laboratory of Medicines (LNM), an institution under the Portuguese Ministry of Defense, is advancing in the production of medical cannabis, according to information from Cannareporter.
Historically linked to the Portuguese Army, the LNM has recently signed a contract for the construction of clean rooms for medical cannabis. This initiative, costing approximately 183,000 euros, aims to meet the medical needs of Portuguese patients by offering a potential alternative or complement to existing pharmaceutical options.
For more news like this, along with all the latest in legalization, research, and lifestyle, download our free cannabis news app.
Contract and Construction of the Clean Room
As reported by Cannareporter, the contract, signed in August 2023, is for the construction of clean rooms. The contract stipulates a completion period of 144 days and was awarded to TypeSolution S.A., a company specializing in laboratory and industrial equipment consulting. TypeSolution S.A. has worked with several Portuguese clients in the medical cannabis sector, including Tilray, CannPrisma, and LabialFarma.
Although Portuguese legislation allows the LNM to contribute to the production of cannabis-based medicines, the specific nature of their participation remains unclear. The LNM’s engagement in cannabis could help alleviate the bureaucratic burden associated with exceptional use authorizations (equivalent to France’s ATU) and reduce the high acquisition costs of existing cannabis-based medicines such as Epidyolex or Sativex.
The exact objectives of the infrastructure under development and whether the LNM intends to create specific medical products based on cannabis remain uncertain, as Cannareporter has not received a more precise response from the LNM.
LNM’s Role in the SkanAbility Project and Research Consortium
The LNM is also involved in the “SkanAbility” project, a research consortium launched in 2020. This project, which includes industrial players, the Faculty of Pharmacy of the University of Lisbon, and the University of Minho, aimed to develop formulations for functional cosmetics and aromatherapy incorporating cannabinoids and terpenes.
The goal of the project, as detailed in the text, was to create formulations, including creams, emulsions, topicals, or enriched oils, with purified cannabinoids and terpenes extracted from cannabis flowers or leaves.
LNM’s Specific Task in “SkanAbility”
In the “SkanAbility” project, categorized specifically as “T106,” the LNM’s task was to create a cannabis biobank using biological samples and recording comprehensive characterization data. Cannareporter suggests that the planning and design of the biobank’s support structure have been completed, and the implementation of the physical infrastructure is underway.
Furthermore, the LNM has executed another crucial task related to the project: the planning and creation of a quality management plan for handling biological samples. This involves ensuring the safety, transport, storage, and traceability of processes associated with the proper conservation and handling of samples. An additional mention is made of the development of a digital registry dedicated to managing the biobank’s database.
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.